Natixis Advisors LLC Sells 3,936 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors LLC cut its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 10.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,659 shares of the biopharmaceutical company’s stock after selling 3,936 shares during the period. Natixis Advisors LLC’s holdings in Cytokinetics were worth $1,583,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of CYTK. Pathstone Holdings LLC lifted its stake in Cytokinetics by 17.0% during the third quarter. Pathstone Holdings LLC now owns 34,560 shares of the biopharmaceutical company’s stock worth $1,825,000 after purchasing an additional 5,027 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Cytokinetics in the 3rd quarter valued at $248,000. Intech Investment Management LLC bought a new stake in Cytokinetics in the third quarter valued at $1,725,000. Massachusetts Financial Services Co. MA raised its stake in Cytokinetics by 24.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 344,448 shares of the biopharmaceutical company’s stock worth $18,187,000 after acquiring an additional 68,381 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Cytokinetics by 42.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company’s stock valued at $69,769,000 after acquiring an additional 395,709 shares during the period.

Analyst Ratings Changes

A number of equities analysts have commented on CYTK shares. Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Thursday, February 6th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a report on Friday, February 28th. JMP Securities restated a “market outperform” rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Stifel Nicolaus began coverage on Cytokinetics in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price objective for the company. Finally, Morgan Stanley set a $67.00 target price on Cytokinetics in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average price target of $82.00.

Cytokinetics Trading Up 2.5 %

Shares of Cytokinetics stock opened at $46.57 on Tuesday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics, Incorporated has a 52 week low of $40.53 and a 52 week high of $75.71. The stock has a 50 day moving average price of $45.96 and a two-hundred day moving average price of $49.82. The stock has a market capitalization of $5.51 billion, a PE ratio of -8.66 and a beta of 0.95.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million. As a group, equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Robert I. Blum sold 16,970 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.44, for a total value of $737,176.80. Following the transaction, the chief executive officer now directly owns 364,181 shares of the company’s stock, valued at approximately $15,820,022.64. The trade was a 4.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00. Following the sale, the executive vice president now owns 116,071 shares of the company’s stock, valued at $5,724,621.72. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,834 shares of company stock worth $1,949,275 over the last 90 days. 3.40% of the stock is currently owned by corporate insiders.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.